BPC-157 is a synthetic 15-amino acid peptide derived from a gastric cytoprotective protein, with one of the most extensive preclinical research records of any compound in the tissue-repair peptide literature — spanning more than 40 published animal studies produced primarily by the Zagreb group (Sikiric et al.) since 1994. What separates BPC-157 from most synthetic peptides in research is its documented oral bioactivity: unlike the majority of peptides that are degraded in the gastrointestinal tract, BPC-157 maintains stability in gastric juice — a property that has made it the subject of both oral gavage and systemic injection protocols in rodent model research.
This article is a research documentation guide. It reviews the BPC-157 dosing protocol parameters that have appeared in published preclinical literature — including route-specific dose ranges from rodent model studies, frequency parameters, reconstitution methodology, and storage stability data. All dose data described here reflects what investigators administered to animal subjects under controlled experimental conditions. This is not human dosing guidance.
Pure Grade Labs supplies BPC-157 10MG as a lyophilised research chemical, verified by HPLC and mass spectrometry with a batch-specific COA. It is available individually or as part of the Injury Recovery Research Stack alongside TB-500. Supplied strictly for laboratory research purposes — not for human consumption.
Key Takeaways
- The BPC-157 preclinical research literature documents intraperitoneal (IP) dose ranges of approximately 1–10 mcg/kg in rodent models — with 10 mcg/kg being the most commonly cited parameter across published Sikiric et al. studies from 1994 to 2024.
- BPC-157 is unusual among synthetic peptides for its documented stability in gastric juice, which has driven a parallel oral gavage research strand alongside the dominant IP injection protocol literature.
- Published research designs most commonly use once-daily administration, with study durations ranging from acute single-dose to 28-day repeat-dose rodent protocols — 14-day and 28-day designs being the most represented in the literature.
- Reconstitution for laboratory use follows standard bacteriostatic water protocol; lyophilised BPC-157 is documented as stable for up to 18 months at −20°C, with reconstituted solution stable for approximately 28 days at 4°C.
- Compliance note: All dose parameters in this article are extracted from published animal research studies. BPC-157 is not approved by the MHRA for human use. The information below is academic documentation of preclinical methodology — not human dosing guidance. For research use only.
Source Research-Grade BPC-157
HPLC-verified purity. Batch-specific COA. Lyophilised. Supplied strictly for laboratory research — not for human consumption.
View BPC-157 10MG →BPC-157 in Preclinical Research Literature
Body Protection Compound-157 — BPC-157 — is a synthetic pentadecapeptide derived from a naturally occurring protein isolated from gastric juice. Its CAS number is 137525-51-0; its molecular weight is 1419.5 Da. The sequence is: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — 15 amino acids arranged in a stable configuration that resists enzymatic degradation more effectively than most synthetic peptides of comparable size.
The BPC-157 research literature is unusually concentrated. The dominant research group is the laboratory of Professor Predrag Sikiric at the University of Zagreb, Croatia, whose team has published the majority of primary studies on this compound since 1994. Supplementary research from Chang et al. (2011) in Journal of Applied Physiology, Gwyer et al. (2019) in Cell and Tissue Research, and DeFoor et al. (2024) in Arthroscopy provide independent replication and mechanistic validation of the Zagreb group's preclinical findings.
The compound has been investigated in rodent models across a range of tissue types and experimental injury paradigms — including musculoskeletal (tendon, ligament, bone), gastrointestinal (ulcer models, bowel anastomosis), neurological (traumatic brain injury, spinal cord transection), and systemic (multiple organ failure) research designs. This breadth of experimental application, combined with the volume of publications, gives BPC-157 one of the most detailed preclinical research footprints of any non-approved peptide in the current literature.
Importantly for research design, BPC-157 is stable in both gastric acid and plasma — a property validated explicitly by Sikiric et al. in early characterisation work. This gastric stability drives the oral gavage research strand and distinguishes BPC-157 from the vast majority of synthetic peptides that require parenteral administration to achieve systemic bioavailability.
Research Protocol Parameters Documented in Literature
Research Documentation Notice
The parameters below are extracted from published animal research studies. They describe what investigators administered to rodent subjects under controlled experimental conditions. This is academic documentation of preclinical methodology — not human dosing guidance.
Across the published BPC-157 preclinical literature, a consistent set of experimental parameters emerges. In preclinical rodent models, investigators most commonly administered BPC-157 via intraperitoneal injection, with the dose range most frequently documented falling between 1 mcg/kg and 10 mcg/kg of body weight. The 10 mcg/kg parameter appears most frequently across Sikiric et al. publications, while lower dose comparators (1 mcg/kg, 2 mcg/kg) are used in dose-response studies to establish the compound's effective range in rodent models.
In preclinical models employing oral gavage, researchers have administered BPC-157 dissolved in drinking water or via direct gavage administration — typically at similar mcg/kg parameters to IP protocols, adjusted in some studies to account for differing bioavailability characteristics. The oral research strand is particularly notable because BPC-157's gastric stability theoretically permits systemic effects via the enteral route — a property being investigated in gastrointestinal, systemic, and CNS research models.
Dose Ranges by Route in Preclinical Models
Intraperitoneal (IP) Administration
In preclinical rodent models, investigators have most commonly used the intraperitoneal route for BPC-157 administration. The documented dose range across published IP protocols is approximately 1–10 mcg/kg. The 10 mcg/kg parameter is the most consistently cited figure in the Sikiric group's publications across diverse injury models (tendon transection, bowel anastomosis, gastric ulcer, CNS trauma). In dose-ranging experiments within the literature, investigators have compared 1 mcg/kg versus 10 mcg/kg to establish dose-dependent effects, with some studies including a 5 mcg/kg mid-range comparator group.
Oral Gavage Administration
In preclinical models investigating oral bioactivity, investigators have administered BPC-157 dissolved in saline or directly in drinking water at parameters consistent with the IP range (1–10 mcg/kg equivalents). The oral route research strand is methodologically significant because it tests BPC-157's stability hypothesis — that a peptide capable of surviving gastric acid digestion may exert systemic effects through the enteral absorption pathway. Published research using the oral route has documented comparable outcome parameters to IP studies in gastrointestinal and systemic experimental models.
Systemic and Topical Administration
A smaller strand of the BPC-157 literature has examined systemic (intravenous) and topical administration in rodent models, particularly in wound healing and skin tissue research designs. In preclinical systemic protocols, researchers have used mcg/kg parameters broadly consistent with the IP literature. Topical application research has typically used local concentration parameters rather than weight-based dosing, with investigators applying BPC-157 dissolved in saline directly to wound sites in experimental models. This topical research strand is less developed than the IP literature and represents an area of ongoing preclinical investigation.
Frequency Parameters in Research Studies
In preclinical rodent model studies, once-daily administration is the most commonly documented frequency parameter across the BPC-157 literature. The majority of Sikiric et al. publications describe a once-daily IP injection protocol beginning at the time of experimental injury induction and continuing through the designated study endpoint — typically 14 or 28 days in musculoskeletal and tissue repair research designs.
In acute experimental paradigms — such as single-dose challenge studies or immediate post-injury single administration designs — investigators have documented acute-phase outcomes following a single administration at the 10 mcg/kg IP parameter. These acute single-dose designs are used to characterise early-phase biological responses rather than sustained tissue-level outcomes, which require repeat-dose protocols in rodent models.
Some published gastrointestinal research designs have administered BPC-157 continuously via drinking water across the full study duration, rather than as discrete daily injections — allowing investigators to model prolonged enteral exposure in rodent GI tissue models. This continuous oral exposure design is specific to GI research applications and is not interchangeable with the discrete IP injection methodology used in musculoskeletal and CNS research designs.
Reconstitution and Laboratory Preparation
BPC-157 as supplied by Pure Grade Labs is a lyophilised powder in a sealed pharmaceutical-grade vial. Laboratory reconstitution follows the standard peptide protocol used across the preclinical research literature: the vial is reconstituted with bacteriostatic water — sterile water containing 0.9% benzyl alcohol as a bacteriostatic agent, which prevents microbial growth in reconstituted solution during refrigerated storage.
Concentration Calculation
The reconstituted concentration depends on the volume of bacteriostatic water added to the vial. A 10MG BPC-157 vial reconstituted with 2mL of bacteriostatic water yields a solution of 5mg/mL (5000 mcg/mL). Reconstituted with 10mL, the same vial yields 1mg/mL (1000 mcg/mL). Researchers select their reconstitution volume based on the volume per administration their protocol requires. For precise low-volume delivery in rodent model research, a higher concentration (lower reconstitution volume) is typically preferred to minimise the injection volume administered per subject.
Laboratory Protocol Notes
Standard laboratory practice for peptide reconstitution involves injecting bacteriostatic water slowly into the vial along the glass wall rather than directly onto the lyophilised cake — minimising mechanical disruption to the peptide structure. The vial should be gently swirled (not vortexed) until the lyophilisate is fully dissolved. For research requiring the highest purity standards, pharmaceutical-grade bacteriostatic water is the standard diluent in published protocols.
Research Variables and Stability
Storage conditions are a critical variable in peptide research, directly affecting compound integrity between administration timepoints in repeat-dose protocols. The published and manufacturer-validated stability data for BPC-157 is as follows:
| State | Storage Condition | Documented Stability | Notes |
|---|---|---|---|
| Lyophilised powder | −20°C (sealed vial) | Up to 18 months | Preferred long-term storage condition; protect from light |
| Lyophilised powder | 2–8°C refrigerated | Several months | Suitable for short-term working storage; avoid temperature fluctuation |
| Reconstituted solution | 4°C refrigerated | Up to 28 days | In bacteriostatic water; use within 28 days of reconstitution |
| Reconstituted solution | Room temperature | Not recommended | Peptide degradation accelerates significantly above 8°C; avoid |
Stability data reflects published and manufacturer-validated parameters for research use. All storage and handling should comply with your laboratory's standard operating procedures.
A key variable in BPC-157 research designs is pH of the reconstituted solution. Published studies using saline as diluent (for in vivo administration in rodent models) typically document pH 6.5–7.4. Bacteriostatic water maintains a comparable pH range and is the standard diluent for research storage between administration timepoints. Researchers should avoid reconstituting BPC-157 in acidic diluents, which may affect the peptide's secondary structure despite its inherent acid stability.
BPC-157 Research Period Structures in Literature
Published BPC-157 preclinical research can be broadly categorised by study duration. Three distinct temporal structures appear in the literature, each suited to different experimental endpoints:
Acute Single-Dose Studies
In acute experimental designs, investigators administer a single dose at injury induction and measure outcomes over 24–72 hours. These designs are used primarily to characterise early-phase biological responses — acute inflammatory markers, early gene expression changes, and immediate tissue-level events in standardised rodent injury models. Single-dose acute studies dominate the gastrointestinal and organ protection literature where rapid cytoprotective responses are the primary endpoint.
Short-Duration Protocols: 1–2 Weeks
One- to two-week once-daily IP protocols appear in the published literature for experiments examining early-phase tissue organisation outcomes — including tendon and ligament research designs where the primary endpoints are early collagen organisation, fibroblast activity, and vascular response parameters. Chang et al. (2011) used a comparable short-duration protocol to examine tendon repair responses in a rat Achilles tendon transection model, documenting differences in biomechanical and histological parameters at the two-week endpoint between BPC-157 and vehicle control groups.
Extended Protocols: 3–4+ Weeks
The majority of musculoskeletal and systemic research designs in the BPC-157 literature use 28-day (4-week) repeat-dose protocols. This duration captures the full acute-to-remodelling phase of tissue repair in rodent models and provides sufficient time to detect biomechanical, histological, and functional outcome differences between experimental and control groups. Four-week protocols with once-daily IP administration at 10 mcg/kg represent the most replicable experimental design in the BPC-157 rodent model literature and form the methodological backbone of the Sikiric group's published body of work.
A researcher designing a 28-day rodent tendon repair study following the published Sikiric methodology would typically: randomise subjects into vehicle control and BPC-157 treatment groups; perform standardised injury induction at Day 0 (e.g., Achilles tendon transection); begin once-daily IP administration of BPC-157 at 10 mcg/kg in saline from Day 0 or Day 1; continue through Day 28; then perform endpoint assessment combining biomechanical testing (tensile load to failure), histological analysis (collagen organisation, fibroblast density, vascularisation), and functional scoring. This is the template design underlying the majority of published positive findings in the BPC-157 musculoskeletal literature. The protocol is documented here for research methodology reference only.
Key Preclinical Studies: Documented Parameters
| Study | Model | Route & Dose Range | Duration | Primary Outcome Measured |
|---|---|---|---|---|
| Sikiric et al. (1994) | Rat gastric ulcer model | IP & oral; 1–10 mcg/kg | 7–14 days | Gastric mucosal integrity, ulcer healing parameters in rodent model |
| Chang CH et al. (2011) | Rat Achilles tendon transection | IP; ~10 mcg/kg | 14 days | Tendon biomechanical properties, collagen organisation, fibroblast response |
| Sikiric et al. (2018) | Multiple rodent injury models | IP & oral; 10 mcg/kg | 14–28 days | Review of cytoprotective and tissue repair endpoints across model types |
| Gwyer, Wragg, Wilson (2019) | Review: rodent wound models | IP & topical; 1–10 mcg/kg | 7–28 days | Soft tissue healing, vascularisation, growth factor expression in wound models |
| DeFoor MT et al. (2024) | Rodent joint/tendon model | IP; ~10 mcg/kg | 28 days | Articular tissue parameters, joint-level histological and mechanical endpoints |
All parameters reflect published preclinical animal research. For research methodology reference only. Not for human use. Sources: Sikiric P et al. 2018 (PMID: 29879893); DeFoor MT et al. 2024 (PMC12313605); Chang CH et al. 2011 (J Appl Physiol); Gwyer D, Wragg NM, Wilson SL. 2019 (Cell Tissue Res. 377(2):153-159).
Injury Recovery Research Stack
BPC-157 + TB-500 — the two most extensively studied tissue repair peptides in the preclinical literature. HPLC verified. Batch COAs on every order.
View the Research Stack →Frequently Asked Questions
What dose of BPC-157 is documented in preclinical research?
In preclinical rodent models, investigators have most commonly documented intraperitoneal administration at 10 mcg/kg — with the range across published studies spanning approximately 1–10 mcg/kg. The 10 mcg/kg parameter appears in the majority of Sikiric et al. publications across diverse tissue research applications. These are animal research parameters, not human dosing guidance.
What routes of administration appear in the BPC-157 research literature?
Published preclinical literature documents four routes: intraperitoneal injection (most common), oral gavage (driven by BPC-157's documented gastric acid stability), systemic/intravenous administration, and topical application. IP injection dominates the musculoskeletal research literature; oral administration is most represented in GI tissue research designs.
How long do BPC-157 research studies typically run in the literature?
Published BPC-157 preclinical study durations range from single-dose acute protocols (24–72 hour outcomes) through to 28-day repeat-dose designs. The 14-day and 28-day protocol structures are the most common in the musculoskeletal tissue research literature. Four-week once-daily IP protocols represent the most replicable research design across the published evidence base.
How should BPC-157 be reconstituted for laboratory use?
Standard laboratory protocol uses bacteriostatic water as the diluent for BPC-157 reconstitution. The concentration achieved depends on the volume added — a 10MG vial reconstituted with 2mL yields 5mg/mL; with 10mL yields 1mg/mL. The lyophilised peptide should be allowed to dissolve by gentle swirling, not vortexing. Reconstituted solution should be stored at 4°C and used within 28 days.
What are the storage conditions for BPC-157?
Lyophilised BPC-157 is stable at −20°C for up to 18 months in sealed vials. Short-term working storage at 2–8°C is acceptable for periods of several months. Reconstituted solution should be stored at 4°C and used within 28 days. Avoid repeated freeze-thaw cycles, which accelerate peptide degradation. Protect from direct light exposure in all storage conditions.
Is BPC-157 legal to purchase for research in the UK?
BPC-157 is not a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016, and is not listed as a prescription-only medicine (POM) under the Human Medicines Regulations 2012. It is legally available as a research chemical in the UK. Pure Grade Labs supplies BPC-157 strictly for laboratory research purposes. Not for human consumption.
Pure Grade Standard — Every Batch Verified
BPC-157, TB-500, Bacteriostatic Water and the complete tissue research range. HPLC verified. Batch COAs available. Research use only.
Get Pure Grade BPC-157 →Summary
The BPC-157 preclinical research literature is one of the most consistent bodies of evidence for any non-approved synthetic peptide. Across 40+ publications spanning three decades, investigators have converged on a relatively narrow set of experimental parameters: intraperitoneal administration at 1–10 mcg/kg in rodent models (10 mcg/kg being the most commonly documented), once-daily frequency, and study durations of 14–28 days for tissue repair endpoints. A parallel oral gavage research strand — made possible by BPC-157's documented gastric acid stability — adds methodological breadth to the literature and makes BPC-157 unique among synthetic peptides in preclinical research.
For researchers sourcing BPC-157 for laboratory investigation, the key supply-side considerations are purity verification (HPLC and mass spectrometry), storage condition compliance, and reconstitution methodology. Pure Grade Labs supplies BPC-157 10MG with batch-specific COAs confirming purity. The Injury Recovery Research Stack pairs BPC-157 with TB-500 for researchers investigating tissue repair endpoints across both the BPC-157 and thymosin beta-4 literature. All compounds are supplied for research purposes only — not for human consumption.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Curr Pharm Des. 2018;24(18):1942–1955. Focus on BPC-157 as a therapy for gastrointestinal and musculoskeletal system healing. PMID: 29879893
- DeFoor MT, Frank RM, et al. Arthroscopy. 2024. Preclinical evaluation of BPC-157 in joint and tendon repair models. PMC: PMC12313605
- Chang CH, Tsai WC, Hsu YH, Pang JH. J Appl Physiol. 2011;110(3):774–780. BPC-157 enhances tendon outgrowth in rat Achilles tendon transection model. Study documenting fibroblast proliferation and tendon repair parameters in rodent model.
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC-157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159. PMID reference for tissue review; doi:10.1007/s00441-019-03016-8
Last Updated: May 2026